Servier: patent settlements were not by-object restrictions
A lawyer for pharmaceutical company Servier said the EU’s antitrust watchdog incorrectly found that agreements delaying the entry of generic rivals to its cardiovascular drug perindopril were by-object restrictions.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now